Edition:
United States

InVivo Therapeutics Holdings Corp (NVIV.OQ)

NVIV.OQ on NASDAQ Stock Exchange Capital Market

1.99USD
14 Aug 2018
Change (% chg)

-- (--)
Prev Close
$1.99
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
65,956
52-wk High
$55.00
52-wk Low
$1.64

Latest Key Developments (Source: Significant Developments)

Invivo Therapeutics Reports Q2 Loss Per Share Of $7.48
Tuesday, 7 Aug 2018 04:30pm EDT 

Aug 7 (Reuters) - InVivo Therapeutics Holdings Corp ::INVIVO THERAPEUTICS REPORTS 2018 SECOND QUARTER FINANCIAL RESULTS.Q2 LOSS PER SHARE $7.48.  Full Article

Invivo Therapeutics Reports Q1 Loss Per Share Of $3.34
Monday, 7 May 2018 04:30pm EDT 

May 7 (Reuters) - InVivo Therapeutics Holdings Corp ::INVIVO THERAPEUTICS REPORTS 2018 FIRST QUARTER FINANCIAL RESULTS.Q1 LOSS PER SHARE $3.34.  Full Article

Invivo Therapeutics Announces Reverse Stock Split
Monday, 9 Apr 2018 08:00am EDT 

April 9 (Reuters) - InVivo Therapeutics Holdings Corp ::INVIVO THERAPEUTICS PROVIDES BUSINESS UPDATE.25 REVERSE STOCK SPLIT OF ITS COMMON STOCK.ANTICIPATES REVERSE STOCK SPLIT WILL BECOME EFFECTIVE AT 5:00 P.M. EASTERN TIME ON APRIL 16, 2018.RELATED SAVINGS OF ABOUT $3 MILLION THROUGH 2019.PROJECTS AVERAGE CASH BURN OVER LAST THREE QUARTERS OF 2018 TO BE APPROXIMATELY $1 MILLION PER MONTH.IN CONNECTION WITH REVERSE STOCK SPLIT, AUTHORIZED SHARES WILL BE REDUCED FROM 100 MILLION SHARES TO FOUR MILLION SHARES.  Full Article

Invivo Therapeutics Receives FDA Approval For Controlled Trial Of The Neuro-Spinal Scaffold™
Thursday, 8 Mar 2018 08:00am EST 

March 8 (Reuters) - Invivo Therapeutics Holdings Corp ::INVIVO THERAPEUTICS RECEIVES FDA APPROVAL FOR PIVOTAL, RANDOMIZED, CONTROLLED TRIAL OF THE NEURO-SPINAL SCAFFOLD™ IN PATIENTS WITH ACUTE SPINAL CORD INJURY.  Full Article

InVivo Therapeutics Appoints Richard Toselli As Chief Executive Officer
Monday, 5 Feb 2018 08:00am EST 

Feb 5 (Reuters) - Invivo Therapeutics Holdings Corp ::INVIVO THERAPEUTICS ANNOUNCES APPOINTMENT OF RICHARD TOSELLI, M.D., AS PRESIDENT AND CHIEF EXECUTIVE OFFICER.INVIVO THERAPEUTICS - ‍TOSELLI HAS BEEN APPOINTED TO BOARD AND WILL CONTINUE TO SERVE IN HIS CAPACITY AS INVIVO'S CHIEF MEDICAL OFFICER​.INVIVO THERAPEUTICS HOLDINGS CORP - RICHARD TOSELLI HAS BEEN APPOINTED PRESIDENT AND CEO OF INVIVO.  Full Article

InVivo Therapeutics Announces Latest Results From INSPIRE
Wednesday, 3 Jan 2018 08:00am EST 

Jan 3 (Reuters) - InVivo Therapeutics Holdings Corp ::INVIVO THERAPEUTICS ANNOUNCES LATEST RESULTS FROM INSPIRE AND PROVIDES UPDATE ON PROPOSED CLINICAL PATH FORWARD.INVIVO THERAPEUTICS HOLDINGS - 19 PATIENTS IMPLANTED WITH NEURO-SPINAL SCAFFOLD;3 PATIENTS DIED WITHIN 2 WEEKS OF IMPLANTATION​ IN STUDY.INVIVO THERAPEUTICS HOLDINGS CORP - ‍16 EVALUABLE PATIENTS HAVE NOW ALL REACHED SIX-MONTH PRIMARY ENDPOINT VISIT IN STUDY​.INVIVO THERAPEUTICS - ‍DOES NOT ANTICIPATE REOPENING ENROLLMENT IN INSPIRE,EXPECTS TO PROVIDE ADDITIONAL CLARITY ON CLINICAL PATH FORWARD IN Q2 2018​.  Full Article

InVivo Therapeutics Announces Executive Management And Board Changes
Monday, 18 Dec 2017 08:00am EST 

Dec 18 (Reuters) - InVivo Therapeutics Holdings Corp ::INVIVO THERAPEUTICS ANNOUNCES EXECUTIVE MANAGEMENT AND BOARD CHANGES.INVIVO THERAPEUTICS HOLDINGS CORP - ‍RICHARD TOSELLI, NAMED ACTING CHIEF EXECUTIVE OFFICER​.INVIVO THERAPEUTICS HOLDINGS CORP - ‍ TOSELLI REPLACES MARK PERRIN, WHO HAS RESIGNED AS CEO AND CHAIRMAN OF INVIVO'S BOARD OF DIRECTORS​.INVIVO THERAPEUTICS HOLDINGS CORP - ‍ TOSELLI WILL CONTINUE TO SERVE IN HIS CAPACITY AS INVIVO'S CHIEF MEDICAL OFFICER​.INVIVO THERAPEUTICS HOLDINGS CORP - ANN MERRIFIELD WAS APPOINTED AS CHAIR OF BOARD OF DIRECTORS​.  Full Article

InVivo Therapeutics reports Q3 loss per share $0.28
Monday, 30 Oct 2017 04:45pm EDT 

Oct 30 (Reuters) - InVivo Therapeutics Holdings Corp :InVivo Therapeutics provides business update and reports 2017 third quarter financial results.Q3 adjusted loss per share $0.19 excluding items.Q3 loss per share $0.28.  Full Article

InVivo Therapeutics Holdings Corp - ‍ expects restructuring to be substantially completed by end of Q3 2017
Monday, 28 Aug 2017 04:50pm EDT 

Aug 28 (Reuters) - InVivo Therapeutics Holdings Corp :InVivo Therapeutics Holdings Corp - ‍ expects restructuring to be substantially completed by end of Q3 2017, to be fully completed by end of Q4 of 2017​.InVivo Therapeutics Holdings Corp says ‍restructuring is expected to extend company's cash runway into beginning of Q3 of 2018 - SEC filing​.InVivo Therapeutics Holdings - ‍expects restructuring will result in total restructuring charges of about $810,000-$1.1 million during year ending Dec 31, 2017.InVivo Therapeutics Holdings-on Aug 28, co notified Thomas Ulich, co's chief scientific officer,that his employment to be terminated effective Aug 30, 2017​.  Full Article

Invivo Therapeutics reports strategic corporate restructuring
Monday, 28 Aug 2017 04:30pm EDT 

Aug 28 (Reuters) - Invivo Therapeutics Holdings Corp ::Invivo Therapeutics announces strategic corporate restructuring.Invivo Therapeutics - ‍company is undergoing a reduction in force (rif), in which it is eliminating 13 positions, or approximately 39 pct of its workforce​.Invivo Therapeutics - ‍company is evaluating strategic options for allowing cell and gene therapy programs to move forward outside of company​.Invivo Therapeutics Holdings Corp - ‍plans to restart cervical study once FDA approves a protocol that allows for enrollment in united states​.Invivo Therapeutics Holdings- ‍as part of decision to focus on inspire, announced suspension of chronic sci stem cell, gene therapy research programs​.Invivo Therapeutics- ‍as part of decision to focus on inspire, also announced halt in enrollment into canadian cervical study of neuro-spinal scaffold​.Invivo Therapeutics Holdings - ‍restructuring actions all together are projected to result in 2018 operating expense savings of approximately $7.3 million​.Invivo Therapeutics Holdings -restructuring actions all together projected to reduce 2018 cash burn from about $2.0 million/month to about $1.5 million/month.  Full Article